Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation

Hematology/ Oncology and Stem Cell Therapy

Volumn 10, Issue 4, 2017, Pages 233-238

  Camargo, Jose F ^a   Komanduri, Krishna V ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Cytomegalovirus; Hematopoietic stem cell transplantation; Immune reconstitution; Lymphocytes

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAVIR; BETA CHEMOKINE; BRINCIDOFOVIR; CIDOFOVIR; CORTICOSTEROID; CYTOKINE; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; LETERMOVIR; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR; VALGANCICLOVIR;

ANTIVIRAL THERAPY; BACTEREMIA; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL DECISION MAKING; COLITIS; CORD BLOOD STEM CELL TRANSPLANTATION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; DONOR; DRUG MEGADOSE; ENCEPHALITIS; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LYMPHOCYTE; MORBIDITY; MORTALITY RATE; MORTALITY RISK; PATHOGENESIS; PNEUMONIA; RETINITIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY INFECTION; SERODIAGNOSIS; SYSTEMIC MYCOSIS; T CELL DEPLETION; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION; VIRUS RESISTANCE; ALLOGRAFT; CYTOMEGALOVIRUS; DECISION MAKING; IMMUNOLOGY; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ALLOGRAFTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DECISION MAKING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; T-LYMPHOCYTES;

EID: 85021248059     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hemonc.2017.05.001     Document Type: Review

References (65)

1. Boeckh, M., Geballe, A.P., Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 121 (2011), 1673–1680.
2. Boeckh, M., Ljungman, P., How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113 (2009), 5711–5719.
3. de la Camara, R., CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis, 8, 2016, e2016031.
4. El Chaer, F., Shah, D.P., Chemaly, R.F., How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood 128 (2016), 2624–2636.
5. Ljungman, P., Hakki, M., Boeckh, M., Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 25 (2011), 151–169.
6. Broers, A.E., van Der Holt, R., van Esser, J.W., Gratama, J.W., Henzen-Logmans, S., Kuenen-Boumeester, V., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 95 (2000), 2240–2245.
7. Craddock, C., Szydlo, R.M., Dazzi, F., Olavarria, E., Cwynarski, K., Yong, A., et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 112 (2001), 228–236.
8. Kollman, C., Howe, C.W., Anasetti, C., Antin, J.H., Davies, S.M., Filipovich, A.H., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (2001), 2043–2051.
9. Nakamura, R., Battiwalla, M., Solomon, S., Follmann, D., Chakrabarti, S., Cortez, K., et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 10 (2004), 49–57.
10. Teira, P., Battiwalla, M., Ramanathan, M., Barrett, A.J., Ahn, K.W., Chen, M., et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127 (2016), 2427–2438.
11. Kalra, A., Williamson, T., Daly, A., Savoie, M.L., Stewart, D.A., Khan, F., et al. Impact of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin-conditioned hematopoietic cell transplantation. Biol Blood Marrow Transplant 22 (2016), 1654–1663.
12. Ozdemir, E., Saliba, R.M., Champlin, R.E., Couriel, D.R., Giralt, S.A., de Lima, M., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40 (2007), 125–136.
13. Komanduri, K.V., St John, L.S., de Lima, M., McMannis, J., Rosinski, S., McNiece, I., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 110 (2007), 4543–4551.
14. Boeckh, M., Leisenring, W., Riddell, S.R., Bowden, R.A., Huang, M.L., Myerson, D., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101 (2003), 407–414.
15. Reusser, P., Riddell, S.R., Meyers, J.D., Greenberg, P.D., Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78 (1991), 1373–1380.
16. Erard, V., Guthrie, K.A., Seo, S., Smith, J., Huang, M., Chien, J., et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis 61 (2015), 31–39.
17. Marr, K.A., Carter, R.A., Boeckh, M., Martin, P., Corey, L., Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002), 4358–4366.
18. Nichols, W.G., Corey, L., Gooley, T., Davis, C., Boeckh, M., High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 185 (2002), 273–282.
19. Green, M.L., Leisenring, W., Xie, H., Mast, T.C., Cui, Y., Sandmaier, B.M., et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3 (2016), e119–e127.
20. Camargo, J.F., Shimose, L., Bueno, M.X., Rosa, R., Jeyakumar, N., Morris, M.I., et al. Impact of viral load on eradication of cytomegalovirus (CMV) viremia amongst high-risk allogeneic stem cell transplant (SCT) recipients. Open Forum Infect Dis, 3(Suppl. 1), 2016, 2290.
21. Garcia-Vidal, C., Upton, A., Kirby, K.A., Marr, K.A., Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 47 (2008), 1041–1050.
22. Thursky, K., Byrnes, G., Grigg, A., Szer, J., Slavin, M., Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004), 115–121.
23. Marr, K.A., Seidel, K., White, T.C., Bowden, R.A., Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181 (2000), 309–316.
24. Boeckh, M., Nichols, W.G., Chemaly, R.F., Papanicolaou, G.A., Wingard, J.R., et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 162 (2015), 1–10.
25. Gimenez, E., Munoz-Cobo, B., Solano, C., Amat, P., Navarro, D., Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value?. J Clin Microbiol 52 (2014), 654–656.
26. Gimeno, C., Solano, C., Latorre, J.C., Hernandez-Boluda, J.C., Clari, M.A., Remigia, M.J., et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 46 (2008), 3311–3318.
27. Green, M.L., Leisenring, W., Stachel, D., Pergam, S.A., Sandmaier, B.M., Wald, A., et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1687–1699.
28. Green, M.L., Leisenring, W.M., Xie, H., Walter, R.B., Mielcarek, M., Sandmaier, B.M., et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122 (2013), 1316–1324.
29. Mariotti, J., Maura, F., Spina, F., Roncari, L., Dodero, A., Farina, L., et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20 (2014), 885–890.
30. Milano, F., Pergam, S.A., Xie, H., Leisenring, W.M., Gutman, J.A., Riffkin, I., et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 118 (2011), 5689–5696.
31. Panagou, E., Zakout, G., Keshani, J., Smith, C., Irish, D., Mackinnon, S., et al. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants. Transplant Infect Dis 18 (2016), 405–414.
32. Peres, R.M., Costa, C.R., Andrade, P.D., Bonon, S.H., Albuquerque, D.M., de Oliveira, C., et al. Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. BMC Infect Dis, 10, 2010, 147.
33. Solano, C., Munoz-Cobo, B., Gimenez, E., Remigia, M.J., Amat, P., Clari, M.A., et al. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center. Bone Marrow Transplant 48 (2013), 1010–1012.
34. Tan, S.K., Waggoner, J.J., Pinsky, B.A., Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients. J Clin Virol 69 (2015), 179–183.
35. Torre-Cisneros, J., Caston-Osorio, J.J., Martin, C., Rivero, A., Doblas, A., Rojas, R., et al. Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients. Enferm Infecc Microbiol Clin 28 (2010), 6–12.
36. Avery, R.K., Marty, F.M., Strasfeld, L., Lee, I., Arrieta, A., Chou, S., et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transplant Infect Dis 12 (2010), 489–496.
37. Marty, F.M., Boeckh, M., Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?. Curr Opin Virol 1 (2011), 555–562.
38. Marty, F.M., Ljungman, P., Papanicolaou, G.A., Winston, D.J., Chemaly, R.F., Strasfeld, L., et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11 (2011), 284–292.
39. Camargo, J.F., Morris, M.I., Abbo, L.M., Simkins, J., Saneeymehri, S., Alencar, M.C., et al. The use of brincidofovir for the treatment of mixed dsDNA viral infection. J Clin Virol 83 (2016), 1–4.
40. El-Haddad, D., El Chaer, F., Vanichanan, J., Shah, D.P., Ariza-Heredia, E.J., Mulanovich, V.E., et al. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience. Antiviral Res 134 (2016), 58–62.
41. Marty, F.M., Winston, D.J., Rowley, S.D., Vance, E., Papanicolaou, G.A., Mullane, K.M., et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369 (2013), 1227–1236.
42. Chemaly, R.F., Ullmann, A.J., Stoelben, S., Richard, M.P., Bornhauser, M., Groth, C., et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370 (2014), 1781–1789.
43. Melendez, D.P., Razonable, R.R., Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist 8 (2015), 269–277.
44. La Rosa, C., Longmate, J., Martinez, J., Zhou, Q., Kaltcheva, T.I., Tsai, W., et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood 129 (2017), 114–125.
45. Wang, X., Wong, C.W., Urak, R., Mardiros, A., Budde, L.E., Chang, W.C., et al. CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells. Clin Cancer Res 21 (2015), 2993–3002.
46. Preiksaitis, J.K., Hayden, R.T., Tong, Y., Pang, X.L., Fryer, J.F., Heath, A.B., et al. Are we there yet? Impact of the First International Standard for Cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis 63 (2016), 583–589.
47. Ljungman, P., Boeckh, M., Hirsch, H.H., Josephson, F., Lundgren, J., Nichols, G., et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64 (2017), 87–91.
48. Komanduri, K.V., Donahoe, S.M., Moretto, W.J., Schmidt, D.K., Gillespie, G., Ogg, G.S., et al. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects. Virology 279 (2001), 459–470.
49. Sylwester, A.W., Mitchell, B.L., Edgar, J.B., Taormina, C., Pelte, C., Ruchti, F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202 (2005), 673–685.
50. Ozdemir, E., St John, L.S., Gillespie, G., Rowland-Jones, S., Champlin, R.E., Molldrem, J.J., et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 100 (2002), 3690–3697.
51. Krol, L., Stuchly, J., Hubacek, P., Keslova, P., Sedlacek, P., Stary, J., et al. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Bone Marrow Transplant 46 (2011), 1089–1098.
52. Kim, T.K., St John, L.S., Wieder, E.D., Khalili, J., Ma, Q., Komanduri, K.V., Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production. J Immunol 183 (2009), 6167–6174.
53. Komanduri, K.V., Wieder, E.D., Benjamin, C.L., Levy, R.B., The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression. Immunol Res 57 (2013), 140–150.
54. Price, D.A., Bitmansour, A.D., Edgar, J.B., Walker, J.M., Axthelm, M.K., Douek, D.C., et al. Induction and evolution of cytomegalovirus-specific CD4+ T cell clonotypes in rhesus macaques. J Immunol 180 (2008), 269–280.
55. Betts, M.R., Nason, M.C., West, S.M., De Rosa, S.C., Migueles, S.A., Abraham, J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006), 4781–4789.
56. Buggert, M., Tauriainen, J., Yamamoto, T., Frederiksen, J., Ivarsson, M.A., Michaelsson, J., et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog, 10, 2014, e1004251.
57. Gasser, O., Bihl, F., Sanghavi, S., Rinaldo, C., Rowe, D., Hess, C., et al. Treatment-dependent loss of polyfunctional CD8+ T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation. Am J Transplant 9 (2009), 794–803.
58. Gimenez, E., Munoz-Cobo, B., Solano, C., Amat, P., de la Camara, R., Nieto, J., et al. Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8(+) T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation. Transpl Infect Dis 17 (2015), 361–370.
59. Lilleri, D., Fornara, C., Chiesa, A., Caldera, D., Alessandrino, E.P., Gerna, G., Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 93 (2008), 248–256.
60. Pelak, O., Stuchly, J., Krol, L., Hubacek, P., Keslova, P., Sedlacek, P., et al. Appearance of CMV specific T-cells predicts fast resolution of viremia post hematopoietic stem cell transplantation. Cytometry B Clin Cytom, 2017, 10.1002/cyto.b.21348 In press.
61. Fleming, T., Dunne, J., Crowley, B., Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J Med Virol 82 (2010), 433–440.
62. Lilleri, D., Gerna, G., Fornara, C., Lozza, L., Maccario, R., Locatelli, F., Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108 (2006), 1406–1412.
63. Waldrop, S.L., Pitcher, C.J., Peterson, D.M., Maino, V.C., Picker, L.J., Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 99 (1997), 1739–1750.
64. Komanduri, K.V., Feinberg, J., Hutchins, R.K., Frame, R.D., Schmidt, D.K., Viswanathan, M.N., et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 183 (2001), 1285–1289.
65. Komanduri, K.V., Viswanathan, M.N., Wieder, E.D., Schmidt, D.K., Bredt, B.M., Jacobson, M.A., et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4 (1998), 953–956.